CD105 expression is an independent predictor of survival in patients with endometrial cancer

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1007-1011

  Erdem, Ozlem ^a   Taskiran, Cagatay ^a   Onan, M Anil ^a   Erdem, Mehmet ^a   Guner, Haldun ^a   Ataoglu, Omur ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; CD105; CD34; Endometrial cancer; Survival; VEGF

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; ENDOGLIN; VASCULOTROPIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; MYOMETRIUM; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; UNIVERSITY HOSPITAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TURKEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33751419491     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.010     Document Type: Article

References (26)

1. DiSaia P.J., and Creasman W.T. Adenocarcinoma of the uterus. In: DiSaia P.J., and Creasman W.T. (Eds). Clinical Gynecologic Oncology. 6th ed. (2002), Mosby, Philadelphia 137-172
2. Rasila K.K., Burger R.A., Smith H., Lee F.C., and Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int. J. Gynecol. Cancer 15 (2005) 710-726
3. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
4. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
5. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin. Diagn. Pathol. 10 (1993) 302-313
6. Bodey B., Bodey Jr. B., Siegel S.E., and Kaiser H.E. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neovascularization. Anticancer Res. 18 (1998) 3621-3628
7. Kaku T., Hirakawa T., Kamura T., Amada S., Kinukawa N., Kabayashi H., et al. Angiogenesis in adenocarcinoma of the uterine cervix. Cancer 83 (1998) 1384-1390
8. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-Correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 1-8
9. Yokoyama Y., Sato S., Futagami M., Fukushi Y., Sakamoto T., Umemoto M., et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol. Oncol. 77 (2000) 413-418
10. Folkman J., and Haudenshild C. Angiogenesis in vitro. Nature 288 (1980) 551-556
11. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
12. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84 (1992) 1875-1887
13. Appleton M.A., Attanoos R.L., and Jasani B. Thrombomodulin B as a marker of vascular and lymphatic tumours. Histopathology 29 (1996) 153-157
14. Mietinnen M., Lindenmayer A.E., and Chaubal A. Endothelial cell markers CD31, CD34, BNH9 antibody to H- and Y-antigens: evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod. Pathol. 7 (1994) 82-90
15. Abulafia O., Treist W.E., Sherer D.M., Hansen C.C., and Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet. Gynecol. 86 (1995) 479-485
16. Wang J.M., Kumar S., Pye D., Haboubi N., and Al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. Natl. Cancer Inst. 86 (1994) 386-388
17. Lindenmayer A.E., and Miettinen M. Immunophenotypic features of uterine stromal cells. CD34 expression in endocervical stroma. Virchows Arch. 426 (1995) 457-460
18. Westphal J.R., Willems H.W., Schalkwijk C.J.M., Ruiter D.J., and DeWaal R.M.W. Characteristics and possible function of endoglin. A TGF-b binding protein. Behring-Inst.-Mitt. 92 (1993) 15-22
19. Seon B.K., Matsuno F., Haruta Y., Kondo M., and Bareas M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res. 3 (1997) 1031-1044
20. Saad R.S., Jasnosz K.M., Tung M.Y., and Silverman J.F. Endoglin (CD105) expression in endometrial carcinoma. Int. J. Gynecol. Pathol. 22 (2003) 248-253
21. Kaku T., Kamura T., Kinukawa N., Kobayashi H., Sakai K., Tsuruchi N., et al. Angiogenesis in endometrial carcinoma. Cancer 80 (1997) 741-747
22. Kirshner C.V., Alanis-Amezcua J.M., Martin V.G., Luna N., Morgan E., Yang J.J., et al. Angiogenesis factor in endometrial carcinoma. Am. J. Obstet. Gynecol. 174 (1996) 1879-1884
23. Erdem O., Erdem M., Dursun A., Akyol G., and Erdem A. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int. J. Gynecol. Pathol. 22 (2003) 254-260
24. Salvasen H.B., Gulluoglu M.G., Stefansson I., and Akslen L.A. Significance of CD105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 111 (2003) 1011-1018
25. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 (1995) 1029-1039
26. Lee C.N., Cheng W.F., Chen C.A., Chu J.S., Hsieh C.Y., and Hsieh F.J. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet. Gynecol. 96 (2000) 615-621